Cerebral Amyloid Positivity Prediction Models Using Clinical Data in Subjects With Mild Cognitive Impairment and Dementia
2
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Objective Due to high cost of amyloid imaging, its use of amyloid imaging to confirm amyloid pathology is limited in clinical practice. It is of importance to develop a model to predict cerebral amyloid positivity using clinical data obtained from a memory clinic.Methods A total of 410 participants who had symptom of subjective cognitive decline and underwent amyloid PET and apolipoprotein ε (APOE) genotyping were retrospectively enrolled from January 2016 to January 2019. Models for cerebral amyloid positivity prediction were developed in all subjects, mild cognitive impairment (MCI) subjects, and Alzheimer’s disease (AD) dementia subjects through multivariate logistic regression analysis. The performance of the models was assessed using receiver operating characteristic (ROC) curve analysis and the area under the curve (AUC) values.Results Age, sex, years of education, body mass index (BMI), APOE4, and mini mental state examination score (MMSE) were selected for the final model for all subjects. The AUC value of the ROC curve was 0.775. Age, sex, years of education, BMI, and APOE4 were selected for the final model for MCI subjects. The AUC value was 0.735. Age, sex, years of education, BMI, APOE4, MMSE, and history of hypertension were selected for the final model for AD dementia subjects. The AUC value was 0.845.Conclusion This study found that models using clinical data can predict cerebral amyloid positivity according to cognitive status. These models can be useful as a screening tool predict cerebral amyloid deposition in cognitively impaired patients in a memory clinic.
Abstract
Objective Due to high cost of amyloid imaging, its use of amyloid imaging to confirm amyloid pathology is limited in clinical practice. It is of importance to develop a model to predict cerebral amyloid positivity using clinical data obtained from a memory clinic.Methods A total of 410 participants who had symptom of subjective cognitive decline and underwent amyloid PET and apolipoprotein ε (APOE) genotyping were retrospectively enrolled from January 2016 to January 2019. Models for cerebral amyloid positivity prediction were developed in all subjects, mild cognitive impairment (MCI) subjects, and Alzheimer’s disease (AD) dementia subjects through multivariate logistic regression analysis. The performance of the models was assessed using receiver operating characteristic (ROC) curve analysis and the area under the curve (AUC) values.Results Age, sex, years of education, body mass index (BMI), APOE4, and mini mental state examination score (MMSE) were selected for the final model for all subjects. The AUC value of the ROC curve was 0.775. Age, sex, years of education, BMI, and APOE4 were selected for the final model for MCI subjects. The AUC value was 0.735. Age, sex, years of education, BMI, APOE4, MMSE, and history of hypertension were selected for the final model for AD dementia subjects. The AUC value was 0.845.Conclusion This study found that models using clinical data can predict cerebral amyloid positivity according to cognitive status. These models can be useful as a screening tool predict cerebral amyloid deposition in cognitively impaired patients in a memory clinic.
참고문헌 (28)
- Alzheimer’s Association, "2013 Alzheimer’s disease facts and figures", Alzheimers Dement, 9, pp.208~245 (2013)
- Bateman RJ, "Clinical and biomarker changes in dominantly inherited Alzheimer’s disease", N Engl J Med, 367, pp.795~804 (2012)
- Beach TG, "Accuracy of the clinical diagnosis of Alzheimer disease at National Institute on Aging Alzheimer Disease Centers, 2005-2010", J Neuropathol Exp Neurol, 71, pp.266~273 (2012)
- Ossenkoppele R, "Impact of molecular imaging on the diagnostic process in a memory clinic", Alzheimers Dement, 9, pp.414~421 (2013)
- Johnson KA, "Appropriate use criteria for amyloid PET: a report of the Amyloid Imaging Task Force, the Society of Nuclear Medicine and Molecular Imaging, and the Alzheimer’s Association", Alzheimers Dement, 9, pp.1~16 (2013)
- 안현정, "Seoul Neuropsychological Screening Battery-Dementia Version (SNSB-D): A Useful Tool for Assessing and Monitoring Cognitive Impairments in Dementia Patients", Journal of Korean Medical Science, 25(7), pp.1071~1076 (2010), 대한의학회
- Lee JH, "Development of the Korean version of the Consortium to Establish a Registry for Alzheimer’s Disease Assessment Packet(CERAD-K) : clinical and neuropsychological assessment batteries", J Gerontol B Psychol Sci Soc Sci, 57, pp.P47~ (2002)
- Rascovsky K, "Sensitivity of revised diagnostic criteria for the behavioural variant of frontotemporal dementia", Brain, 134, pp.2456~2477 (2011)
- McKeith IG, "Diagnosis and management of dementia with Lewy bodies : third report of the DLB Consortium", Neurology, 65, pp.1863~1872 (2005)
- Román GC, "Vascular dementia: diagnostic criteria for research studies. Report of the NINDS-AIREN International Workshop", Neurology, 43, pp.250~260 (1993)
- Winblad B, "Mild cognitive impairment--beyond controversies, towards a consensus : report of the International Working Group on Mild Cognitive Impairment", J Intern Med, 256, pp.240~246 (2004)
- Emre M, "Clinical diagnostic criteria for dementia associated with Parkinson’s disease", Mov Disord, 22, pp.1689~1707 (2007)
- American Psychiatric Association, "Diagnostic and Statistical Manual of Mental Disorders(DSM-5®)" (2013), American Psychiatric Pub
- McKhann GM, "The diagnosis of dementia due to Alzheimer’s disease : recommendations from the National Institute on Aging-Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer’s disease", Alzheimers Dement, 7, pp.263~269 (2011)
- Sabri O, "Beta-amyloid imaging with florbetaben", Clin Transl Imaging, 3, pp.13~26 (2015)
- "VizamylTM Flutemetamol F 18 Injection"[URL]
- Bahar-Fuchs A, "Prediction of amyloid-β pathology in amnestic mild cognitive impairment with neuropsychological tests", J Alzheimers Dis, 33, pp.451~462 (2013)
- Burnham SC, "A blood-based predictor for neocortical Aβ burden in Alzheimer’s disease : results from the AIBL study", Mol Psychiatry, 19, pp.519~526 (2014)
- Nakamura A, "High performance plasma amyloid-β biomarkers for Alzheimer’s disease", Nature, 554, pp.249~254 (2018)
- Park JC, "Chemically treated plasma Aβ is a potential blood-based biomarker for screening cerebral amyloid deposition", Alzheimers Res Therapy, 9, pp.20~ (2017)
- Ovod V, "Amyloid β concentrations and stable isotope labeling kinetics of human plasma specific to central nervous system amyloidosis", Alzheimers Dement, 13, pp.841~849 (2017)
- Haghighi M, "Identifying costeffective predictive rules of amyloid-β level by integrating neuropsychological tests and plasma-based markers", J Alzheimers Dis, 43, pp.1261~1270 (2015)
- Lee JH, "Prediction of cerebral amyloid with common information obtained from memory clinic practice", Front Aging Neurosci, 10, pp.309~ (2018)
- Wisniewski T, "APOE-amyloid interaction : therapeutic targets", Neurobiol Dis, 138, pp.104784~ (2020)
- Vemuri P, "Evaluation of amyloid protective factors and alzheimer disease neurodegeneration protective factors in elderly individuals", JAMA Neurol, 74, pp.718~726 (2017)
- Power MC, "Life-course blood pressure in relation to brain volumes", Alzheimers Dement, 12, pp.890~899 (2016)
- Glodzik L, "Alzheimer’s disease markers, hypertension, and gray matter damage in normal elderly", Neurobiol Aging, 33, pp.1215~1227 (2012)
- Wiseman RM, "Hippocampal atrophy, whole brain volume, and white matter lesions in older hypertensive subjects", Neurology, 63, pp.1892~1897 (2004)